Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective
Identifieur interne : 004906 ( Main/Exploration ); précédent : 004905; suivant : 004907Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective
Auteurs : Fabien B. Vincent [Australie] ; Eric F. Morand [Australie] ; Kim Murphy [Australie] ; Fabienne Mackay [Australie] ; Xavier Mariette [France] ; Christian Marcelli [France]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2013-02.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Maladie chronique.
English descriptors
- KwdEn :
- Adab, Adab formation, Adab incidence, Adab levels, Adalimumab, Adalimumab treatment, Adverse events, Ankylosing, Ankylosing spondylitis, Antibody, Antibody formation, Antidrug, Antidrug antibodies, Arthritis, Arthritis rheum, Assay, Bartelds, Baseline, Biological associations, Bowel, Bowel disease, Certolizumab, Certolizumab pegol, Chronic disease, Chronic diseases, Clin, Clinical improvement, Clinical practice, Clinical response, Clinical response association, Concomitant, Correlated, Dermatol, Different mechanism, Disease activity, Dose escalation, Elisa, Elisa elisa, Engl, Etanercept, Gastroenterol, Golimumab, Gottlieb, Hanauer, Heijde, Human igg1, Human necrosis factor, Igg1, Immune, Immune complexes, Immunogenicity, Inflammatory disease, Infusion, Infusion intervals, Infusion reaction, Infusion reactions, Inhibitor, Kavanaugh, Keystone, Lancet, Level association, Lower frequency, Maintenance therapy, Mease, Methotrexate, Moderate infusion reactions, Monash university, Monoclonal, Monoclonal antibody, Multicenter, Necrosis, Necrosis factor, Nurmohamed, Pegol, Plaque psoriasis, Psoriasis, Psoriatic, Psoriatic arthritis, Randomised, Randomized, Receptor, Rheum, Rheumatoid, Rheumatoid arthritis, Rheumatoid arthritis patients, Rheumatol, Rheumatology, Safety results, Sandborn, Secondary failure, Serum trough, Spondylitis, Statistical analysis, Subcutaneous, Tmtnf, Trough serum, Tumor necrosis factor, Tumour, Tumour necrosis factor, Vries, Wolbink.
- Teeft :
- Adab, Adab formation, Adab incidence, Adab levels, Adalimumab, Adalimumab treatment, Adverse events, Ankylosing, Ankylosing spondylitis, Antibody, Antibody formation, Antidrug, Antidrug antibodies, Arthritis, Arthritis rheum, Assay, Bartelds, Baseline, Biological associations, Bowel, Bowel disease, Certolizumab, Certolizumab pegol, Chronic diseases, Clin, Clinical improvement, Clinical practice, Clinical response, Clinical response association, Concomitant, Correlated, Dermatol, Different mechanism, Disease activity, Dose escalation, Elisa, Elisa elisa, Engl, Etanercept, Gastroenterol, Golimumab, Gottlieb, Hanauer, Heijde, Human igg1, Human necrosis factor, Igg1, Immune, Immune complexes, Immunogenicity, Infusion, Infusion intervals, Infusion reaction, Infusion reactions, Inhibitor, Kavanaugh, Keystone, Lancet, Level association, Lower frequency, Maintenance therapy, Mease, Methotrexate, Moderate infusion reactions, Monash university, Monoclonal, Monoclonal antibody, Multicenter, Necrosis, Necrosis factor, Nurmohamed, Pegol, Plaque psoriasis, Psoriasis, Psoriatic, Psoriatic arthritis, Randomised, Randomized, Receptor, Rheum, Rheumatoid, Rheumatoid arthritis, Rheumatoid arthritis patients, Rheumatol, Safety results, Sandborn, Secondary failure, Serum trough, Spondylitis, Statistical analysis, Subcutaneous, Tmtnf, Trough serum, Tumour, Tumour necrosis factor, Vries, Wolbink.
Abstract
The introduction of biologics, especially tumour necrosis factor (TNF) inhibitors, has revolutionized the management of chronic inflammatory diseases. However, at least one third of patients with these diseases, receiving TNF inhibitors either do not respond to treatment, or lose initial responsiveness. For a significant proportion, improvement of clinical response is achieved after switching to another anti-TNF drug, suggesting a basis for failure unrelated to the therapeutic target itself. A likely explanation for this is immunogenicity, as all biologics are potentially immunogenic, and the resulting anti-drug antibodies (ADAb) can theoretically decrease the efficacy of biologics and/or induce adverse events. Indeed, in these chronic inflammatory diseases, many studies have now established correlations between ADAb formation, low serum drug levels, and the failure or loss of response to anti-TNF antibodies. This article will review key findings related to ADAb, and propose a model wherein monitoring of drug levels and ADAb may be a predictive tool leading to a better choice of biologics. Such an approach could improve chronic inflammatory disease management toward a personalized and more cost-effective approach.
Url:
DOI: 10.1136/annrheumdis-2012-202545
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002917
- to stream Istex, to step Curation: 002917
- to stream Istex, to step Checkpoint: 000216
- to stream Main, to step Merge: 004A30
- to stream PascalFrancis, to step Corpus: 000C65
- to stream PascalFrancis, to step Curation: 005199
- to stream PascalFrancis, to step Checkpoint: 000B10
- to stream Main, to step Merge: 005284
- to stream Main, to step Curation: 004906
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective</title><author><name sortKey="Vincent, Fabien B" sort="Vincent, Fabien B" uniqKey="Vincent F" first="Fabien B" last="Vincent">Fabien B. Vincent</name></author><author><name sortKey="Morand, Eric F" sort="Morand, Eric F" uniqKey="Morand E" first="Eric F" last="Morand">Eric F. Morand</name></author><author><name sortKey="Murphy, Kim" sort="Murphy, Kim" uniqKey="Murphy K" first="Kim" last="Murphy">Kim Murphy</name></author><author><name sortKey="Mackay, Fabienne" sort="Mackay, Fabienne" uniqKey="Mackay F" first="Fabienne" last="Mackay">Fabienne Mackay</name></author><author><name sortKey="Mariette, Xavier" sort="Mariette, Xavier" uniqKey="Mariette X" first="Xavier" last="Mariette">Xavier Mariette</name></author><author><name sortKey="Marcelli, Christian" sort="Marcelli, Christian" uniqKey="Marcelli C" first="Christian" last="Marcelli">Christian Marcelli</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DCAEC499C66FC471323E4B914AC2089B937BFDBE</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1136/annrheumdis-2012-202545</idno><idno type="url">https://api.istex.fr/document/DCAEC499C66FC471323E4B914AC2089B937BFDBE/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002917</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002917</idno><idno type="wicri:Area/Istex/Curation">002917</idno><idno type="wicri:Area/Istex/Checkpoint">000216</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000216</idno><idno type="wicri:doubleKey">0003-4967:2013:Vincent F:antidrug:antibodies:adab</idno><idno type="wicri:Area/Main/Merge">004A30</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:13-0074411</idno><idno type="wicri:Area/PascalFrancis/Corpus">000C65</idno><idno type="wicri:Area/PascalFrancis/Curation">005199</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000B10</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000B10</idno><idno type="wicri:doubleKey">0003-4967:2013:Vincent F:antidrug:antibodies:adab</idno><idno type="wicri:Area/Main/Merge">005284</idno><idno type="wicri:Area/Main/Curation">004906</idno><idno type="wicri:Area/Main/Exploration">004906</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective</title><author><name sortKey="Vincent, Fabien B" sort="Vincent, Fabien B" uniqKey="Vincent F" first="Fabien B" last="Vincent">Fabien B. Vincent</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Immunology, Monash University, Central Clinical School, Alfred Medical Research and Education Precinct (AMREP), Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Morand, Eric F" sort="Morand, Eric F" uniqKey="Morand E" first="Eric F" last="Morand">Eric F. Morand</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Centre for Inflammatory Diseases, Southern Clinical School, Monash University, Monash Medical Centre, Clayton, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Murphy, Kim" sort="Murphy, Kim" uniqKey="Murphy K" first="Kim" last="Murphy">Kim Murphy</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Immunology, Monash University, Central Clinical School, Alfred Medical Research and Education Precinct (AMREP), Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Mackay, Fabienne" sort="Mackay, Fabienne" uniqKey="Mackay F" first="Fabienne" last="Mackay">Fabienne Mackay</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Immunology, Monash University, Central Clinical School, Alfred Medical Research and Education Precinct (AMREP), Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Mariette, Xavier" sort="Mariette, Xavier" uniqKey="Mariette X" first="Xavier" last="Mariette">Xavier Mariette</name><affiliation wicri:level="4"><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, Université Paris-Sud, AP-HP, Groupe Hospitalier Universitaire Paris-Sud, INSERM U1012, 78 rue du Général Leclerc, Le Kremlin Bicêtre</wicri:regionArea><orgName type="university">Université Paris-Sud</orgName><placeName><settlement type="city">Orsay</settlement><region type="region" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Marcelli, Christian" sort="Marcelli, Christian" uniqKey="Marcelli C" first="Christian" last="Marcelli">Christian Marcelli</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Department of Rheumatology, University Hospital Centre of Caen, avenue de la Côte de Nacre, Caen</wicri:regionArea><placeName><region type="region">Région Normandie</region><region type="old region">Basse-Normandie</region><settlement type="city">Caen</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2013-02">2013-02</date><biblScope unit="volume">72</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="165">165</biblScope></imprint><idno type="ISSN">0003-4967</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0003-4967</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adab</term><term>Adab formation</term><term>Adab incidence</term><term>Adab levels</term><term>Adalimumab</term><term>Adalimumab treatment</term><term>Adverse events</term><term>Ankylosing</term><term>Ankylosing spondylitis</term><term>Antibody</term><term>Antibody formation</term><term>Antidrug</term><term>Antidrug antibodies</term><term>Arthritis</term><term>Arthritis rheum</term><term>Assay</term><term>Bartelds</term><term>Baseline</term><term>Biological associations</term><term>Bowel</term><term>Bowel disease</term><term>Certolizumab</term><term>Certolizumab pegol</term><term>Chronic disease</term><term>Chronic diseases</term><term>Clin</term><term>Clinical improvement</term><term>Clinical practice</term><term>Clinical response</term><term>Clinical response association</term><term>Concomitant</term><term>Correlated</term><term>Dermatol</term><term>Different mechanism</term><term>Disease activity</term><term>Dose escalation</term><term>Elisa</term><term>Elisa elisa</term><term>Engl</term><term>Etanercept</term><term>Gastroenterol</term><term>Golimumab</term><term>Gottlieb</term><term>Hanauer</term><term>Heijde</term><term>Human igg1</term><term>Human necrosis factor</term><term>Igg1</term><term>Immune</term><term>Immune complexes</term><term>Immunogenicity</term><term>Inflammatory disease</term><term>Infusion</term><term>Infusion intervals</term><term>Infusion reaction</term><term>Infusion reactions</term><term>Inhibitor</term><term>Kavanaugh</term><term>Keystone</term><term>Lancet</term><term>Level association</term><term>Lower frequency</term><term>Maintenance therapy</term><term>Mease</term><term>Methotrexate</term><term>Moderate infusion reactions</term><term>Monash university</term><term>Monoclonal</term><term>Monoclonal antibody</term><term>Multicenter</term><term>Necrosis</term><term>Necrosis factor</term><term>Nurmohamed</term><term>Pegol</term><term>Plaque psoriasis</term><term>Psoriasis</term><term>Psoriatic</term><term>Psoriatic arthritis</term><term>Randomised</term><term>Randomized</term><term>Receptor</term><term>Rheum</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatoid arthritis patients</term><term>Rheumatol</term><term>Rheumatology</term><term>Safety results</term><term>Sandborn</term><term>Secondary failure</term><term>Serum trough</term><term>Spondylitis</term><term>Statistical analysis</term><term>Subcutaneous</term><term>Tmtnf</term><term>Trough serum</term><term>Tumor necrosis factor</term><term>Tumour</term><term>Tumour necrosis factor</term><term>Vries</term><term>Wolbink</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Anticorps</term><term>Facteur nécrose tumorale</term><term>Maladie chronique</term><term>Maladie inflammatoire</term><term>Rhumatologie</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Adab</term><term>Adab formation</term><term>Adab incidence</term><term>Adab levels</term><term>Adalimumab</term><term>Adalimumab treatment</term><term>Adverse events</term><term>Ankylosing</term><term>Ankylosing spondylitis</term><term>Antibody</term><term>Antibody formation</term><term>Antidrug</term><term>Antidrug antibodies</term><term>Arthritis</term><term>Arthritis rheum</term><term>Assay</term><term>Bartelds</term><term>Baseline</term><term>Biological associations</term><term>Bowel</term><term>Bowel disease</term><term>Certolizumab</term><term>Certolizumab pegol</term><term>Chronic diseases</term><term>Clin</term><term>Clinical improvement</term><term>Clinical practice</term><term>Clinical response</term><term>Clinical response association</term><term>Concomitant</term><term>Correlated</term><term>Dermatol</term><term>Different mechanism</term><term>Disease activity</term><term>Dose escalation</term><term>Elisa</term><term>Elisa elisa</term><term>Engl</term><term>Etanercept</term><term>Gastroenterol</term><term>Golimumab</term><term>Gottlieb</term><term>Hanauer</term><term>Heijde</term><term>Human igg1</term><term>Human necrosis factor</term><term>Igg1</term><term>Immune</term><term>Immune complexes</term><term>Immunogenicity</term><term>Infusion</term><term>Infusion intervals</term><term>Infusion reaction</term><term>Infusion reactions</term><term>Inhibitor</term><term>Kavanaugh</term><term>Keystone</term><term>Lancet</term><term>Level association</term><term>Lower frequency</term><term>Maintenance therapy</term><term>Mease</term><term>Methotrexate</term><term>Moderate infusion reactions</term><term>Monash university</term><term>Monoclonal</term><term>Monoclonal antibody</term><term>Multicenter</term><term>Necrosis</term><term>Necrosis factor</term><term>Nurmohamed</term><term>Pegol</term><term>Plaque psoriasis</term><term>Psoriasis</term><term>Psoriatic</term><term>Psoriatic arthritis</term><term>Randomised</term><term>Randomized</term><term>Receptor</term><term>Rheum</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatoid arthritis patients</term><term>Rheumatol</term><term>Safety results</term><term>Sandborn</term><term>Secondary failure</term><term>Serum trough</term><term>Spondylitis</term><term>Statistical analysis</term><term>Subcutaneous</term><term>Tmtnf</term><term>Trough serum</term><term>Tumour</term><term>Tumour necrosis factor</term><term>Vries</term><term>Wolbink</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Maladie chronique</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">The introduction of biologics, especially tumour necrosis factor (TNF) inhibitors, has revolutionized the management of chronic inflammatory diseases. However, at least one third of patients with these diseases, receiving TNF inhibitors either do not respond to treatment, or lose initial responsiveness. For a significant proportion, improvement of clinical response is achieved after switching to another anti-TNF drug, suggesting a basis for failure unrelated to the therapeutic target itself. A likely explanation for this is immunogenicity, as all biologics are potentially immunogenic, and the resulting anti-drug antibodies (ADAb) can theoretically decrease the efficacy of biologics and/or induce adverse events. Indeed, in these chronic inflammatory diseases, many studies have now established correlations between ADAb formation, low serum drug levels, and the failure or loss of response to anti-TNF antibodies. This article will review key findings related to ADAb, and propose a model wherein monitoring of drug levels and ADAb may be a predictive tool leading to a better choice of biologics. Such an approach could improve chronic inflammatory disease management toward a personalized and more cost-effective approach.</div></front></TEI><affiliations><list><country><li>Australie</li><li>France</li></country><region><li>Basse-Normandie</li><li>Région Normandie</li><li>Île-de-France</li></region><settlement><li>Caen</li><li>Orsay</li></settlement><orgName><li>Université Paris-Sud</li></orgName></list><tree><country name="Australie"><noRegion><name sortKey="Vincent, Fabien B" sort="Vincent, Fabien B" uniqKey="Vincent F" first="Fabien B" last="Vincent">Fabien B. Vincent</name></noRegion><name sortKey="Mackay, Fabienne" sort="Mackay, Fabienne" uniqKey="Mackay F" first="Fabienne" last="Mackay">Fabienne Mackay</name><name sortKey="Morand, Eric F" sort="Morand, Eric F" uniqKey="Morand E" first="Eric F" last="Morand">Eric F. Morand</name><name sortKey="Murphy, Kim" sort="Murphy, Kim" uniqKey="Murphy K" first="Kim" last="Murphy">Kim Murphy</name></country><country name="France"><region name="Île-de-France"><name sortKey="Mariette, Xavier" sort="Mariette, Xavier" uniqKey="Mariette X" first="Xavier" last="Mariette">Xavier Mariette</name></region><name sortKey="Marcelli, Christian" sort="Marcelli, Christian" uniqKey="Marcelli C" first="Christian" last="Marcelli">Christian Marcelli</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004906 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004906 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:DCAEC499C66FC471323E4B914AC2089B937BFDBE
|texte= Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective
}}
| This area was generated with Dilib version V0.6.33. |  |